Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Benzinga

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Valneva SE (NASDAQ:VALN) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness.

Benzinga

Streeting vows not to let drug firms ‘rip off’ taxpayers after pricing row

The Health Secretary on Friday left talks with the pharmaceuticals sector after both sides failed to agree changes to a drug pricing deal.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

What is the row between Wes Streeting and pharmaceutical companies about?

Health secretary has accused firms of being ‘shortsighted’ during dispute over terms for provision of drugs to the NHS

The Guardian - UK

Wes Streeting criticises ‘shortsighted’ drug firms for rejecting pricing offer

Exclusive: Health secretary says he will not let patients be ‘ripped off’ by pharmaceutical companies amid standoff

The Guardian - UK

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Benzinga

Breaking the Bottleneck: How Verseon is Rewriting the Future of Drug Discovery Beyond Pharma's Limits

Verseon is transforming drug discovery with physics-based design, breaking pharma's limits to deliver safer, faster treatments across major diseases.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System

Drug pricing talks between the U.K. government and pharmaceutical companies collapsed Friday, with industry leaders warning the standoff could deter investment. Health Secretary Wes Streeting described the government's offer as "unprecedented," but drugmakers argued that it still imposed excessive costs and requested to negotiate directly with Prime Minister Keir Starmer.

Benzinga

Fury as Tech CEO Sues Uber After Being Assaulted by Illegal Immigrant Driver — Then Losing His Account

Biotech CEO Bryan Kobel sues Uber after allegedly being brutally assaulted by an undocumented Uber driver who denied his service dog, leaving him with serious injuries and prompting scrutiny of Uber's driver vetting.

International Business Times UK

Wes Streeting’s row with pharma firms grows as they reject NHS drug pricing offer

Drugmakers reject health secretary’s latest offer, meaning ‘unsustainable’ rebate scheme will stay in place

The Guardian - UK

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Benzinga

Tharimmune (THAR) Shares Skyrocket On Promising Opioid Countermeasure Data

Shares of Tharimmune Inc (NASDAQ:THAR) are surging Thursday afternoon after the company on Wednesday announced positive results from a simulation analysis of its lead clinical asset, TH104.

Benzinga

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR…

Benzinga

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

5 Healthcare Stocks On Fire This Week

Five healthcare stocks have emerged as standout performers, posting remarkable week-on-week momentum gains according to the latest Benzinga Edge Ranking report.

Benzinga

Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

Shares of Nordson Corporation (NASDAQ:NDSN) rose sharply in pre-market trading after the company reported better-than-expected third-quarter results.

Benzinga

Tharimmune Rockets 42% After Hours — Adding To Stunning 206% Daytime Rally: What's Going On?

Tharimmune Inc. (NASDAQ:THAR) jumped 42.06% to $5.10 in after-hours trading on Wednesday following positive pharmacokinetic simulation results for its lead drug candidate TH104, designed to prevent respiratory depression from fentanyl exposure.

International Business Times UK

Who Is Anna Bouyzk? Woman Attacks Neighbour with Anti-Semitic Slurs and Said His Dead Daughter Deserved To Die

Anna Bouyzk, wife of biotech entrepreneur Mark Bouzyk, is accused of hurling anti-Semitic slurs at her neighbour David Lubin, whose daughter, a 20-year-old IDF soldier, was killed in Jerusalem.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of novel treatments for autoimmune disorders, where cutting-edge cell therapies hold promise to transform patient care.

Benzinga

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

Benzinga

NovaBay Pharmaceuticals Soars 66% In Pre-Market On $6 Million Investment Deal, CEO Appointment

NovaBay Pharmaceuticals Inc. (NYSE:NBY) surged 66.57% in pre-market trading to $1 on Wednesday, following the announcement of major investment and leadership changes that could prevent the company’s liquidation.

Benzinga

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga

Thermo Fisher Positioned As Biopharma's Partner Of Choice

Could Thermo Fisher Scientific Inc. (NYSE:TMO) be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strategic acquisitions and robust growth potential. William Blair initiated coverage on Tuesday on Thermo Fisher Scientific, citing a strong…

Benzinga

PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Tuesday related to PTC Therapeutics, Inc.‘s (NASDAQ:PTCT) New Drug Application (NDA) for vatiquinone for Friedreich’s ataxia.

Benzinga

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx Holdings Inc (NASDAQ:GDRX) shares are pulling back Tuesday morning, as investors potentially take profits following Monday’s surge. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk to expand access to popular GLP-1 medications.

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.